Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss

(Reuters) -Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug, compared with a 2.4 milligram dose and a placebo, all administered once weekly. In the trial, which included 1,407 participants with obesity, the drug was